GALNT14

Across TCGA pan-cancer cohorts, GALNT14 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GALNT14 data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GALNT14 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GALNT14 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, HNSC, and LUAD are the cancer types where GALNT14 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	1.000	0.600	.009	10	view →
HNSC	DFS	Median	All	0.780	0.365	.013	6	view →
LUAD	DFS	Median	II,III,IV	1.000	0.932	.029	3	view →
LSCC	DFS	Tertile	All	0.696	0.844	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GALNT14–CCRCC (DFS)

Open the CCRCC breakdown →